Federal Register
Notice: FDA has determined the regulatory review period for Eli Lilly and Co.’s Alimta is 4,166 days for the extension of a patent that claims the human drug product.. Alimta in combination with cisplatin is indicated for treating patients with malignant pleural mesothelioma whose disease is unresectable or who are otherwise not candidates for curative surgery. To view this notice, click here.